CTLA4 and autoimmune disease: In preclinical models, anti-CTLA-4 treatment is known to enhance onset and severity of several T cell-mediated experimental autoimmune diseases, including murine models of encephalomyelitis [5,6], myasthenia gravis [7], and type 1 diabetes [8].